Skip to main content

Table 5 Clinicopathologic variables associated with progression-free survival

From: Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study

Variables Univariate analysis Multivariate analysis
HR 95% CI P-value Adjusted HR 95% CI P-value
Histology
  Non-endometrioid vs. endometrioid 3.610 1.463–8.909 0.005 7.322 2.477–21.646 < 0.001
FIGO stage
  IVB vs. IIIC 5.308 0.713–39.521 0.103
CA-125 at diagnosis, IU/ml
  ≥190 vs. <190 1.608 0.702–3.682 0.261
Residual tumor after IDS
  Any RT vs. NGR 2.427 1.008–5.844 0.048 5.934 2.035–17.302 0.001
  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, IDS Interval debulking surgery, RT residual tumor, NGR no gross residual, HR hazard ratio, 95% CI 95% confidence interval